Chief Operating Officer
Alison Lawton is COO at Aura. Before joining Aura, Alison was most recently COO at OvaScience. Prior to that, she spent 23 years in various positions of increasing responsibility at Genzyme Corporation and subsequently as part of Sanofi, following its 2011 acquisition of Genzyme. At Genzyme, Alison served as head of the company’s biosurgery unit, where she was responsible for global orthopedics, surgical and regenerative medicine businesses, and also oversaw global market access. Previously, Alison worked for seven years in the United Kingdom at Parke-Davis. She earned her BS in Pharmacology, with honors, from King’s College London.
Alison serves on the board of directors of Verastem, Inc., and ProQR Therapeutics, both public biopharmaceutical companies. She also served on the board of directors of Cubist Pharmaceuticals for three years until its acquisition by Merck &Co., Inc., in 2015. She currently sits on the scientific advisory board for the Massachusetts Life Science Center. Alison is also past President and Chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for the Cell and Gene Therapy Committee.